Sugi Predict

Sugi Predict / Compounds / SCHEMBL246700

SCHEMBL246700

SCHEMBL246700

COc1cc2ncc([N+](=O)[O-])c(Cl)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 2/20 0.49
▸ PDGFRA P16234 2/20 0.49
▸ ABCG2 Q9UNQ0 3/20 0.48
▸ PIN1 Q13526 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ BACE1 P56817 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ BLM P54132 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ ERBB2 P04626 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ PRKDC P78527 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29744240 1.00 PDGFRB (0.49) PDGFRBPDGFRAABCG2PIN1ACHE
Hydrochloric Acid SCHEMBL26102510 0.99 PDGFRB (0.48) PDGFRBPDGFRAABCG2PIN1ACHE
SCHEMBL28826672 0.90 ENPP1 (0.43) PDGFRBPDGFRAABCG2
SCHEMBL25233608 0.89 PDGFRB (0.43) PDGFRBPDGFRAABCG2PIN1ACHE
SCHEMBL18114309 0.89 PDGFRB (0.43) PDGFRBPDGFRAABCG2PIN1ACHE
SCHEMBL18306125 0.89 PIN1 (0.41) PDGFRBPDGFRAABCG2PIN1ACHE
Hydrochloric Acid SCHEMBL26101563 0.88 PDGFRB (0.42) PDGFRBPDGFRAABCG2PIN1ACHE
SCHEMBL168494 0.86 PIN1 (0.49) PDGFRBPDGFRAABCG2PIN1
SCHEMBL31554570 0.86 PIN1 (0.49) PDGFRBPDGFRAABCG2PIN1
SCHEMBL246386 0.84 PDGFRB (0.50) PDGFRBPDGFRAABCG2ACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4034094-B1 PHOSPHODIESTERASE INHIBITORS AND USE ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) 2026-04-15 — — EP disclosed
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
CN-116574099-A Phosphodiesterase inhibitors and uses 南京征祥医药有限公司 2023-08-11 — — CN disclosed
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-06-13 — — US disclosed
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-06-13 — — US disclosed
US-20230014730-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-01-19 — — US disclosed
CN-115362150-A ENPP1 inhibitor, composition and application thereof 贝达药业股份有限公司 2022-11-18 — — CN disclosed
CN-115151253-A Phosphodiesterase inhibitors and uses thereof 南京征祥医药有限公司 2022-10-04 — — CN disclosed
US-20220220114-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2022-07-14 — — US disclosed
WO-2021061803-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2021-04-01 — — WO disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 — — US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 — — EP disclosed
CN-1252054-C Qinoline derivatives inhibiting effect of growth factors such as VEGF ZENECA LTD (GB) 2006-04-19 — — CN disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 — — WO disclosed
EP-0929526-B1 QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF ASTRAZENECA AB (SE) 2005-07-27 — — EP disclosed
US-6809097-B1 ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY ZENECA LIMITED (GB) 2004-10-26 — — US disclosed
EP-0929526-A1 QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF ZENECA LIMITED (GB) 1999-07-21 — — EP disclosed
WO-1998013350-A1 QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF ZENECA LIMITED (GB) 1998-04-02 — — WO disclosed
EP-0310950-A1 Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes RIKER LABORATORIES, INC. (US) 1989-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET PDGFRB 28/4885PDGFRA 49/4885ABCG2 478/4885
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 PDGFRB 1742/4885PDGFRA 2683/4885ABCG2 3204/4885
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors ENPP1, ENPP3, PDE4A PDGFRB 2380/4885PDGFRA 1516/4885ABCG2 4255/4885
US-20220220114-A1 PHOSPHODIESTERASE INHIBITORS AND USE ENPP1, ENPP3, PDE4A PDGFRB 2032/4885PDGFRA 1916/4885ABCG2 3982/4885
US-20230014730-A1 PHOSPHODIESTERASE INHIBITORS AND USE ENPP1, ENPP3, PDE4A PDGFRB 2032/4885PDGFRA 1916/4885ABCG2 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.